{"id":"rad-ifn","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Chills"},{"rate":"5-20%","effect":"Fever"},{"rate":"5-15%","effect":"Headache"},{"rate":"5-15%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism involves the use of a viral vector to deliver the interferon-alpha gene to cells, which then produce the protein to stimulate an immune response. The goal is to activate the body's immune system to fight cancer cells.","oneSentence":"rAd-IFN is a recombinant adenovirus vector-based gene therapy that expresses interferon-alpha.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:12.221Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06757348","phase":"","title":"Fatty Liver and Pancreatic Steatosis","status":"NOT_YET_RECRUITING","sponsor":"Maria Marta Piskorz","startDate":"2025-09-01","conditions":"Exocrine Pancreatic Insufficiency, Fatty Liver, Nonalcoholic, Pancreatic Steatosis","enrollment":61},{"nctId":"NCT00001379","phase":"PHASE2","title":"Treatment and Natural History Study of Lymphomatoid Granulomatosis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1995-05-05","conditions":"Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma","enrollment":94},{"nctId":"NCT03710876","phase":"PHASE3","title":"Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ferring Ventures Limited","startDate":"2019-01-21","conditions":"Malignant Pleural Mesothelioma","enrollment":53},{"nctId":"NCT02773849","phase":"PHASE3","title":"ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-09-19","conditions":"Superficial Bladder Cancer","enrollment":157},{"nctId":"NCT05936229","phase":"PHASE1, PHASE2","title":"Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-04-01","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT06408129","phase":"","title":"COMPArison of Screening Strategies for Active TuBerculosis (COMPASS-TB)","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2017-01-31","conditions":"Active Tuberculosis, Latent Tuberculosis","enrollment":580},{"nctId":"NCT04781257","phase":"","title":"Early Risk Assessment in Household Contacts (≥10 Years) of TB Patients by New Diagnostic Tests in 3 African Countries","status":"UNKNOWN","sponsor":"Michael Hoelscher","startDate":"2021-03-01","conditions":"Tuberculosis","enrollment":2100},{"nctId":"NCT05847491","phase":"","title":"Latent Tuberculosis in Healthcare Workers - the Reality of a Portuguese Tertiary Hospital","status":"UNKNOWN","sponsor":"Centro Hospitalar do Oeste","startDate":"2022-09-01","conditions":"Tuberculosis","enrollment":100},{"nctId":"NCT03498534","phase":"PHASE4","title":"Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis","status":"WITHDRAWN","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2012-09","conditions":"Latent Tuberculosis, Diabetes Mellitus","enrollment":""},{"nctId":"NCT01687244","phase":"PHASE2","title":"Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer","status":"COMPLETED","sponsor":"FKD Therapies Oy","startDate":"2012-09","conditions":"Superficial Bladder Cancer","enrollment":40},{"nctId":"NCT03220464","phase":"NA","title":"Early Diagnosis of Active Tuberculosis Using Ultra Low-dose Chest CT","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2017-06-20","conditions":"Tuberculosis, Pulmonary, Latent Tuberculosis","enrollment":116},{"nctId":"NCT02712671","phase":"","title":"Testing for Tuberculosis in the United Kingdom HIV Infected Population","status":"UNKNOWN","sponsor":"University College, London","startDate":"2013-06","conditions":"HIV, Latent Tuberculosis","enrollment":300},{"nctId":"NCT01162785","phase":"PHASE1","title":"1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-04","conditions":"Bladder Cancer","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nadofaragene firadenovec"],"phase":"phase_3","status":"active","brandName":"rAd-IFN","genericName":"rAd-IFN","companyName":"Ferring Ventures Limited","companyId":"ferring-ventures-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"rAd-IFN is a recombinant adenovirus vector-based gene therapy that expresses interferon-alpha. Used for Metastatic renal cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}